Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection

Adrienne O’Donnell, Nathan Pham, Leandra Battisti, Rachel Epstein, David Nunes, Deirdre Sawinski, Sara Lodi

1 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America, 2 Department of Gastroenterology, University of Washington, Seattle, Washington, United States of America, 3 Department of Pharmacy, Boston Medical Center, Boston, Massachusetts, United States of America, 4 Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, United States of America, 5 Department of Pediatrics, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, United States of America, 6 Evans Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 7 Nephrology and Transplant Division, Weill Cornell Medical College, New York, New York, United States of America

Abstract

Background

Direct-acting antivirals (DAA) are highly effective at treating Hepatitis C virus (HCV) infection, with a cure rate >95%. However, the effect of DAAs on kidney function remains debated.

Methods

We analyzed electronic health record data for DAA-naive patients with chronic HCV infection engaged in HCV care at Boston Medical Center between 2014 and 2018. We compared the following hypothetical interventions using causal inference methods: 1) initiation of DAA and 2) no DAA initiation. For patients with normal kidney function at baseline (eGFR > 90 ml/min/1.73m²), we estimated and compared the risk for reaching Stage 3 chronic kidney disease (CKD) (eGFR ≤ 60 ml/min/1.73m²) under each intervention. For patients with baseline CKD Stages 2–4 (15 < eGFR ≤ 90 ml/min/1.73m²), we estimated and compared the mean change in eGFR at 2 years after baseline under each intervention. We used the parametric g-formula to adjust our estimates for baseline and time-varying confounders.

Results

First, among 1390 patients with normal kidney function at baseline the estimated 2-year risk difference (95% CI) of reaching Stage 3 CKD for DAA initiation versus no DAA was -1% (-3, 2). Second, among 733 patients with CKD Stage 2–4 at baseline the estimated 2-year mean
difference in change in eGFR for DAA initiation versus no DAA therapy was -3 ml/min/1.73m² (-8, 2).

Conclusions
We found no effect of DAA initiation on kidney function, independent of baseline renal status. This suggests that DAAs may not be nephrotoxic; furthermore, in the short-term, HCV clearance may not improve CKD.

Introduction
Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality throughout the world and has important extrahepatic sequelae [1–3]. In addition to diabetes and cardiovascular disease [4], patients with HCV infection are at increased risk for chronic kidney disease (CKD) and end stage renal disease (ESRD) compared with the general population, possibly due to systematic inflammation and vascular damage [5–7].

Treatment with direct-acting antivirals (DAA) is highly effective at clearing HCV: approximately 95% of patients treated with DAAs achieve a sustained virological response (SVR) equivalent to cure [8–11]. Clinical trials have shown that an SVR following treatment with DAAs is associated with liver function improvements for patients with and without CKD [12–14]. Furthermore, treatment with DAAs has been associated with a reduction in both incidence and severity of extrahepatic manifestations of HCV infection such as diabetes and cardiovascular disease [15]. However, the effect of treatment with DAAs on kidney function remains ambiguous and needs to be further investigated.

Clinical trials that led to DAA approval generally had relatively short follow-up duration and did not estimate the mid- and long-term effect of DAA treatment on kidney function. Recent observational studies using real-world data comparing changes in estimated glomerular filtration rate (eGFR) before and after DAA treatment provide inconsistent results. Some studies observed a stabilization of or an increase in eGFR, while one demonstrated a decline in eGFR, specifically among DAA-treated individuals with normal baseline kidney function [10, 16–20]. However, current HCV guidelines do not recommend routine, frequent renal monitoring after DAA treatment in individuals with normal kidney function [21]. Therefore, studies that compare the pre- and post-DAA rate of eGFR decline could be biased by the frequency of and cause for creatinine measurements. In addition, while clinical trials of DAA therapies did not indicate renal toxicity, there have been concerns about kidney adverse effects, especially in connection with sofosbuvir, which is mainly cleared renally [20, 22, 23].

Target trial emulation is a novel approach to the design of comparative effectiveness studies [24]. With this method, the study design and statistical analysis of an observational study closely emulate the protocol components of a target trial, i.e., the ideal trial a researcher would conduct to answer the research question. We have, therefore, used the target trial approach to estimate the effect of DAA treatment on kidney function by comparing two hypothetical interventions: if all patients had initiated DAA treatment versus if all patients had not initiated DAA treatment.

Methods
Study data
We extracted de-identified electronic health record (EHR) data from the Boston Medical Center Clinical Data Warehouse on all patients with a record of chronic HCV infection between
2014 and 2018. Boston Medical Center is the largest safety net hospital in New England; it serves as a leading primary care provider for Boston’s vulnerable populations, including minority and low-income patients; and it has a large HCV testing and screening program [25, 26]. We collected information on inpatient, outpatient, emergency room visits; laboratory measures; prescriptions; active problem lists (i.e., clinician-compiled list of a patient’s health diagnoses); procedures; insurance status; vital status; and demographic characteristics. Chronic HCV infection was defined as having an HCV-RNA result above the laboratory level of detection or a positive HCV genotype result. We used the CKD-EPI algorithm to calculate eGFR [27, 28]. The Boston University Medical Campus Institutional Review Board approved this study. The need for participant consent was waived by the committee because the data was de-identified.

Target trial emulation
In our real-world data, individuals with CKD or impaired kidney function tended to have more frequent renal monitoring than those with normal kidney function (S1 and S2 Figs). The differential monitoring and the potential bias due to it were important considerations. Additionally, the interpretation of changes in eGFR differs for individuals with and without CKD. Therefore, we designed two separate target trials. In Trial 1 we included patients with normal baseline kidney function, defined as eGFR $>90$ ml/min/1.73m². In Trial 2 we included patients with CKD Stage 2–4 at baseline, defined as eGFR between 15 and 90 ml/min/1.73m². The target trials were identical in all components except for the baseline eGFR inclusion criteria and the outcome definition. We then designed two cohort studies to emulate the protocols of each target trial. S1 and S2 Tables detail the target trials and trial emulations.

Eligibility criteria
Eligible individuals met the following criteria between January 2014 and December 2018: age $\geq 18$ years, chronic HCV infection as described above, no history of kidney transplant or ESRD (defined as CKD Stage 5 or on dialysis), and the presence of a serum creatinine (to compute the baseline eGFR), transaminase, and the platelet measurements within three months of each other (to calculate a Fibrosis-4 [FIB-4] score). In addition, to capture the patients actively engaged in HCV care, we restricted eligibility to individuals with an outpatient visit for HCV infection within three months of their identified HCV infection in the EHR. Individuals who met these eligibility criteria were split into cohort 1 and cohort 2 according to their baseline eGFR and they were analyzed separately. A flow chart of these samples is presented in Fig 1.

Interventions
For both cohorts we compared the following two DAA initiation strategies: 1) initiation of DAA within 3 months of baseline and 2) no DAA initiation. S3 Table details the DAA therapies utilized.

Outcome
The outcome definitions differed by cohort. The outcome for cohort 1 (individuals with normal kidney function) was the development of Stage 3 CKD, defined as the first recorded eGFR $\leq 60$ ml/min/1.73m². The outcome for cohort 2 (individuals with baseline CKD Stage 2–4) was change from baseline eGFR to the last recorded eGFR between 24- and 30-months post-baseline.
Follow-up

For both cohorts, follow-up started at baseline, defined as the earliest date all eligibility criteria were met, and ended at the earliest of one of the following events: death, kidney transplant, ESRD (defined as CKD Stage 5 or on dialysis), 2 years post-baseline, administrative end of follow-up (December 2018), or, in Trial 1, date of outcome. A summary of the study design is presented in Fig 2 [29].

Statistical analyses

We summarized the baseline characteristics of each cohort separately using descriptive statistics.

For cohort 1, we used a time-to-event framework to estimate and compare the 2-year cumulative incidence of reaching Stage 3 CKD under the two DAA initiation strategies. For cohort 2, we estimated and compared the mean 2-year change from baseline eGFR under each intervention. Because standard statistical methods cannot appropriately adjust for time-varying confounding, we used the parametric g-formula to generate adjusted estimates [30–32]. Covariates were chosen a priori based on the co-authors’ clinical judgement and review of the published literature.
Like all causal inference methods, the parametric g-formula estimates the causal effect of a hypothetical intervention (here, the DAA therapy initiation) under the identifiability assumptions (positivity, exchangeability, and consistency) and assumes a correct model specification [30]. The parametric g-formula algorithm has been described in detail elsewhere [33–35]. Briefly, it works in two steps: 1) parametric regression models estimate the joint distribution of the outcome, treatment, and time-varying covariates conditional on previous treatment and covariate history and 2) the estimates in step 1 are used to simulate the distribution of the outcome under each intervention using the Monte Carlo method.

In the first step, continuous and binary time-varying covariates were modeled with separate linear and logistic regression models, respectively. All models adjusted for baseline covariates and the most recent lagged value of time-varying covariates. Baseline covariates included age, sex, race/ethnicity (Hispanic or Latino, White, Black, other), body mass index, education level, HCV genotype, insurance type, degree of liver fibrosis (by fibroscan), HIV coinfection, and diabetes. Time-varying covariates were alanine transaminase (ALT), aspartate transaminase (AST), platelet count, change from baseline eGFR, drug or alcohol use disorder [36], mental illness, outpatient visits, and hypertension. We also treated the timing of the laboratory measurements (AST, ALT, platelet count, eGFR) as potential confounders: we fit logistic regression models for these visit processes with a binary outcome of 1 if a measurement was taken at that...
time and 0 if not. For cohort 1, continuous eGFR was included as an additional baseline covariate, and for cohort 2 CKD stage was included as an additional baseline covariate. Skewed continuous covariates (ALT and AST) were log-transformed for normality. Details on the definition and ascertainment of covariates are presented in S4 Table.

In the second step, we used the parameter estimates from the first step to simulate the post-baseline time-varying covariates and the outcome separately under each of the two interventions. In our real-world data, eGFR is measured sporadically and long periods of time can elapse between measurements. Therefore, we imposed an eGFR measurement after 12 months in individuals without a new measurement.

We used nonparametric bootstrapping with 500 samples to obtain 95% confidence intervals (CI) around our estimates based on percentiles.

To explore the validity of our parametric assumptions, we compared the observed outcome means and time-varying covariates with those predicted by our models (S3 and S4 Figs).

All analyses were conducted in SAS version 9.4 using the publicly available GFORMULA macro [37].

Subgroup analyses
As secondary analyses, we reran the estimation procedure in the following patient subgroups with elevated risk of CKD [38]: those with 1) type II Diabetes, 2) hypertension, and 3) age >45 years. The cut-off for age was chosen according to the bimodality of the distribution of age in the study sample (S5 Fig).

Sensitivity analyses
We conducted several sensitivity analyses to assess the robustness of our results. First, we reran the analysis for both cohort 1 and cohort 2 excluding HCV and HIV coinfected patients [39]. Second, we reran the analysis for both cohorts restricting them to outpatient eGFR measurements only. This was done to attempt to exclude acute renal injuries. Third, we reran the analysis for cohort 1 with the follow-up extended to the database close (2018), and we reran the analysis for cohort 2 with the follow-up extended to 3 years. Fourth, we conducted the analyses with time discretized into months, instead of weeks as was done in the main analysis. Fifth, we ran a series of analyses reordering the time-varying covariates, since each parametric model conditions on past covariates. Sixth, we reran the analyses by 1) imposing an eGFR measurement after 6 months, instead of 12 months, and 2) not imposing a new eGFR measurement. In addition, for cohort 1, we ran a sensitivity analysis defining Stage 3 CKD as the first of two eGFR measurements <60 ml/min/1.73m² to be consistent with the official CKD diagnosis guidelines [23]. We also reran the primary analysis additionally adjusting for concomitant use of nephrotoxic medications (nonsteroidal anti-inflammatory drugs, diuretics, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). Finally, we reran the primary analyses to estimate the effect of treatment with Sofosbuvir-containing regimens on renal function. We did this by censoring patients treated with non-Sofosbuvir-containing regimens at their treatment start date.

Results
Descriptive characteristics at baseline for each cohort are presented in Table 1. Descriptive characteristics stratified by treatment with DAA are presented in S5 Table. Cohort 1 included 1442 eligible patients with normal baseline kidney function. In this group, the median [IQR] age was 49 [35, 57] years, the median [IQR] eGFR was 105 ml/min/1.73m² [98, 114] and 1022 (71%) were male. At baseline, 53% of patients had hypertension and 14% had diabetes. In
cohort 1, 927 (64%) patients initiated DAAs during the follow-up and of these, 538 (58%) initiated within 3 months of baseline. Among the 927 patients who initiated DAAs, 822 (89%) had a post-treatment HCV-RNA measured and 792 of 822 (96%) achieved SVR defined as an undetectable HCV-RNA.

Table 1. Baseline characteristics stratified by cohort.

| Characteristic                  | Cohort 1* (N = 1442) | Cohort 2b (N = 733) |
|--------------------------------|-----------------------|---------------------|
| Age, years                     | 49 [35, 57]           | 59 [53, 64]         |
| Male                           | 1022 (71%)            | 435 (59%)           |
| BMI, kg/m²                      | 27 [24, 31]           | 28 [24, 32]         |
| Race/ethnicity                 |                       |                     |
| Black                          | 466 (32%)             | 332 (45%)           |
| Hispanic or Latino             | 241 (17%)             | 114 (16%)           |
| White                          | 658 (46%)             | 243 (33%)           |
| Other                          | 31 (2%)               | 18 (2%)             |
| Missing                        | 46 (3%)               | 26 (4%)             |
| Health insurance               |                       |                     |
| Public                         | 985 (68%)             | 486 (66%)           |
| Private                        | 88 (6%)               | 100 (14%)           |
| Other                          | 369 (26%)             | 147 (20%)           |
| Level of education             |                       |                     |
| Less than high school          | 522 (36%)             | 325 (44%)           |
| HS degree or more              | 700 (49%)             | 314 (43%)           |
| Missing                        | 220 (15%)             | 94 (13%)            |
| ALT, U/L                       | 58 [37, 108]          | 45 [28, 75]         |
| AST, U/L                       | 52 [35, 90]           | 45 [31, 70]         |
| Platelet count, k/uL           | 209 [161, 257]        | 199 [157, 249]      |
| eGFR, ml/min/1.73m²            | 105 [98, 114]         | 76 [64, 83]         |
| Fibrosis Stage                 |                       |                     |
| F0 –F2                         | 431 (30%)             | 243 (33%)           |
| F3 –F4                         | 230 (16%)             | 163 (22%)           |
| Missing                        | 781 (54%)             | 327 (45%)           |
| Fibrosis-4 Score Category      |                       |                     |
| ≤1.45 (no significant fibrosis)| 694 (48%)             | 230 (31%)           |
| 1.45–3.25 (non-cirrhotic fibrosis) | 441 (31%)             | 321 (44%)           |
| >3.25 (cirrhosis)              | 307 (21%)             | 182 (25%)           |
| Diabetes                       | 195 (14%)             | 189 (26%)           |
| Hypertension                   | 760 (53%)             | 495 (68%)           |
| Recent Diagnosis of Drug Use Disorder | 628 (44%)             | 246 (34%)           |
| Recent Diagnosis of Alcohol Use Disorder | 158 (11%)             | 62 (9%)             |
| Recent Diagnosis of Mental Illness | 185 (13%)             | 65 (9%)             |
| HIV co-infection               | 120 (8%)              | 88 (12%)            |

Median [interquartile range] or frequency (percentage) presented. BMI, body mass index. ALT, alanine transaminase. AST, aspartate transaminase.

*Normal kidney function defined as eGFR>90 ml/min/1.73m².

*bCKD Stage 2–4 defined as 90>eGFR>15 ml/min/1.73m².

Other means such as charity or self-pay.

https://doi.org/10.1371/journal.pone.0268478.t001
In cohort 1, 101 (7%) individuals developed Stage 3 CKD events and 13 died during 3,048 person-years of follow-up. As presented in Table 2, the adjusted estimated 2-year risk (95% CI) of reaching Stage 3 CKD was 5% (3%, 6%) and 5% (4%, 8%) under DAA initiation and no DAA initiation, respectively (risk difference -1% (-3%, 2%)).

Cohort 2 included 733 eligible patients with CKD Stage 2–4 at baseline. In this group, the median [IQR] age was 59 [53, 64] years, the median [IQR] eGFR was 76 [64, 83] ml/min/1.73m$^2$ and 435 (59%) were male. At baseline, 68% had hypertension and 26% had diabetes. In cohort 2, 514 (70%) patients initiated DAA during follow-up and of these, 316 (61%) initiated DAA within 3 months of baseline. Among the 514 who initiated DAA, 494 (96%) had a post-treatment HCV-RNA measured, and 481 of 494 (97%) achieved SVR defined as an undetectable HCV-RNA.

In cohort 2, the observed mean (standard deviation, SD) change from baseline eGFR was 0 (16) ml/min/1.73m$^2$. The adjusted estimated mean (95% CI) change from baseline in eGFR was 0 (-3, 2) ml/min/1.73m$^2$ and 3 (-1, 8) ml/min/1.73m$^2$ under DAA initiation and no DAA initiation, respectively. Compared to no DAA initiation, the mean difference was -3 (-8, 2) ml/min/1.73m$^2$ under DAA initiation. There were 14 deaths during the follow-up in cohort 2.

Results of subgroup analyses are presented in S6–S8 Tables. Individuals with diabetes, with hypertension, or aged >45 years had a higher incidence of CKD Stage 3 (cohort 1) and a faster eGFR decline (cohort 2) at 2 years post-baseline compared to their counterparts without diabetes, without hypertension, or aged ≤45 years. Effect estimates were similar to those in the main analysis, although with lower precision due to smaller sample sizes. The subgroup of patients aged ≤45 years in cohort 2 had too few patients (N = 78) to allow for estimation.

Results from sensitivity analyses were consistent with main results for both cohorts (S6 and S7 Figs). The distribution of the time-varying means predicted by our models were similar to the observed means (S3 and S4 Figs).

**Discussion**

We estimated the causal effect of initiating versus not initiating DAA treatment on kidney function in two cohorts of patients with HCV infection: one with normal kidney function (cohort 1) and one with baseline CKD Stage 2–4 (cohort 2). For those with normal kidney function at baseline, we observed no difference in the risk of reaching Stage 3 CKD had all patients initiated DAA therapy versus had all patients not initiated DAA therapy. Similarly, for those with CKD Stage 2–4 at baseline, we observed no difference in 2-year post-baseline change in eGFR had all versus no patients initiated DAA. These results were robust to several sensitivity analyses that varied analytic decisions and model specification. Additionally, in our
secondary analysis we evaluated patient subgroups which might particularly benefit from treatment and found no effect of DAAs on renal function. Altogether these findings suggest that treatment with DAA for HCV infection neither impairs nor improves renal function over a 2-year period.

Previous observational studies estimated the association between DAA treatment and eGFR trends. Specifically, Driedger et al. reported no notable change in renal function before and after DAA initiation [17]. In another study, Medeiros et al. found no association between sofosbuvir-based DAA regimens and eGFR among a group of patients with baseline eGFR < 45 ml/min/1.73m², but observed improvements in renal function among those with eGFR > 45 ml/min/1.73m² [18]. An observational study by Sise et al. compared eGFR slope one year before and one year after DAA initiation and found no difference among those with baseline eGFR > 60 ml/min/1.73m² but reported improvements among those with baseline eGFR < 60 ml/min/1.73m² [16]. In addition, in a retrospective cohort study of patients treated with ledipasvir/sofosbuvir for HCV genotype 1b, Okubo et al. reported no changes in eGFR from pretreatment to 12 weeks post-treatment among those with CKD Stage 3 [10]. Finally, a prospective observational study with biannual eGFR measurements found no significant difference in eGFR evolution among DAA-treated individuals who did and did not achieve SVR [19]. All these studies compared kidney function before and after DAA treatment, therefore, they were only analyzing patients who received DAA treatment. While this approach allows for control of baseline confounding factors, whereby patients act as their own controls, these estimates might be biased if patients who received DAA treatment had worse (or better) renal function than those who did not [9, 40, 41]. In contrast, we designed our study to include all patients eligible to receive DAA treatment and we adjusted for potential confounders. Despite a different study design, our results are not only consistent with the lack of a clear association between treatment with DAAs and renal function in the literature, but also are generalizable to all patients eligible to receive DAAs.

Our study has important strengths. We used longitudinal data from an urban safety net hospital with a notable HCV testing and screening program, which allowed us to include a diverse patient population. We analyzed this rich source of real-world data with causal inference methods that explicitly adjusted for time-varying confounding and selection bias. Time-varying confounding is intrinsic to this study setting: elevated liver function tests and the presence of certain covariates indicate a more pressing need for treatment, and treatment improves liver function [12, 13]. Selection bias is also present, whereby patients with CKD at baseline have more frequent post-baseline eGFR measurements than individuals with normal renal function [32]. We address both methodological issues by adjusting for variables associated with renal function, including explicit adjustment for renal monitoring frequency. By stratifying patients into cohorts according to baseline renal function, we aimed to reduce the impact of selection bias on our results. Our study explicitly estimated what would have happened had all patients initiated versus not initiated DAA, which differs from, but complements, previous studies that compared renal function before and after DAA therapy. As it would be unethical to conduct a randomized controlled trial (RCT) that assigns some patients to HCV treatment and others not, our study is as close methodologically as possible to an RCT and, notably, enables us to comment upon causation, not merely association.

Our study also has several limitations. First, our methods rely on the assumption of no residual confounding, yet we may not have captured all confounding characteristics. However, we separately analyzed two cohorts with different baseline renal function and clinical and demographic characteristics, and, thus, likely they also had different confounding structures. We found the null effect in both cohorts, therefore, it reinforced our conclusions. Second, retrospective use of EHRs is subject to error: we may have missed deaths, HCV treatments, or
laboratory measurements done outside the hospital system. Third, we used prescriptions to ascertain DAA treatment initiation, but we had no record of medication adherence. Treatment completion rates for DAAs as low as 68% have been reported for HCV infected patients [11]. However, a recent study in an overlapping sub-population at Boston Medical Center found, by comparing chart-reviewed DAA adherence with EHR prescription records, that only 7% of individuals prescribed DAAs never started treatment [42]. Fourth, because of the relatively high eGFR in our sample, we used a baseline eGFR cutoff of 90 ml/min/1.73m$^2$. The cutoff for clinically significant CKD is 60 ml/min/1.73m$^2$, and so future studies with larger sample size and/or more renally impaired patients should replicate this research with the more stringent cutoff [21]. Finally, the majority of individuals who initiated DAA treatment received sofosbuvir-containing regimens, in line with DAA treatment in the United States during the study period. A future study with a larger database, perhaps pooling data across medical centers, may look at the effect of specific DAA combinations on renal function [20].

Despite these limitations, our results have important implications for renal monitoring among patients treated with DAA. Frequency of renal monitoring should remain the same after treatment with DAA as it was before for those with and without renal impairment. According to Kidney Disease: Improving Global Outcomes guidelines, this means at least annual eGFR monitoring for those with normal renal function and 1 to 4+ times per year for those with CKD, depending on severity [21]. Our study suggests DAAs may not be nephrotoxic and that HCV clearance may not restore renal function, but future research should continue to work to elucidate these relationships. In conclusion, we used robust methodology combined with a rich source of data and found no causal effect of DAA treatment on kidney function.

Supporting information

S1 Fig. Proportion of patients with any visit over follow-up stratified by cohort. *p<0.05, **p<0.01, ***p<0.001 for difference in proportion of patients with any visit between cohort 1 and cohort 2. (TIF)

S2 Fig. Proportion of patients with an eGFR measurement over follow-up stratified by cohort. *p<0.05, **p<0.01, ***p<0.001 for difference in proportion of patients with an eGFR measurement between cohort 1 and cohort 2. (TIF)

S3 Fig. Observed versus simulated data for cohort 1. Observed (solid line) versus simulated data (dotted line) under the natural course (i.e., treatment is not imposed). The visit process models are for the timing of the laboratory measurements. (TIF)

S4 Fig. Observed versus simulated data for cohort 2. Observed (solid line) versus simulated data (dotted line) under the natural course (i.e., treatment is not imposed). The visit process models are for the timing of the laboratory measurements. (TIF)

S5 Fig. Histogram of age distribution in study sample. (TIF)

S6 Fig. Sensitivity analyses for cohort 1. Administrative end of follow-up/database close date was December 2018. Reordering covariates refers to the temporal parametric assumptions
made in the model.

S7 Fig. Sensitivity analyses for cohort 2. Administrative end of follow-up/database close date was December 2018. Reordering covariates refers to the temporal parametric assumptions made in the model.

S1 Table. Cohort 1: Details of target trial and emulated trial.

S2 Table. Cohort 2: Details of target trial and emulated trial.

S3 Table. Direct-acting antiviral agents summary.

S4 Table. Ascertainment of diagnoses from EHR.

S5 Table. Descriptive characteristics stratified by observed DAA.

S6 Table. Estimated causal effect of DAA initiation interventions on kidney function stratified by baseline renal function among those with versus without diabetes.

S7 Table. Estimated causal effect of DAA initiation interventions on kidney function stratified by baseline renal function among those with versus without hypertension.

S8 Table. Estimated causal effect of DAA initiation interventions on kidney function stratified by baseline renal function among those age >45 versus age ≤45 years.

Acknowledgments

We thank the patients, clinical team, and database managers at Boston Medical Center for providing us with the electronic health records used in this study.

Author Contributions

Conceptualization: Nathan Pham, Rachel Epstein, David Nunes, Sara Lodi.

Data curation: Leandra Battisti, Sara Lodi.

Formal analysis: Adrienne O’Donnell, Sara Lodi.

Funding acquisition: Sara Lodi.

Investigation: Rachel Epstein, Sara Lodi.

Methodology: Adrienne O’Donnell, Nathan Pham, Leandra Battisti, Rachel Epstein, Deirdre Sawinski, Sara Lodi.

Project administration: Adrienne O’Donnell, Sara Lodi.

Supervision: Adrienne O’Donnell, David Nunes, Sara Lodi.
Writing – original draft: Adrienne O'Donnell.
Writing – review & editing: Adrienne O’Donnell, Nathan Pham, Leandra Battisti, Rachel Epstein, David Nunes, Deirdre Sawinski, Sara Lodi.

References

1. Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: A narrative review. J Adv Res. 2017; 8(2):113–130. https://doi.org/10.1016/j.jare.2016.07.004 PMID: 28149647

2. Tsui JL, Vittinghoff E, Shlipak MG, Bertoenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007; 167(12):1271–1276. https://doi.org/10.1001/archinte.167.12.1271 PMID: 17592100

3. Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kostman JR. Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clin Infect Dis. 2015; 61(12):142–156. https://doi.org/10.1093/cid/civ677 PMID: 26270682

4. Su FH, Su CT, Chang SN, Chen PC, Sung FC, Lin CC, et al. Association of hepatitis C virus infection with risk of ESRD: A population-based study. Am J Kidney Dis. 2012; 60(4):553–560. https://doi.org/10.1053/j.ajkd.2012.04.003 PMID: 22554802

5. Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014; 9(6):e100790. https://doi.org/10.1371/journal.pone.0100790 PMID: 24971499

6. Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clin Infect Dis. 2015; 61(12):1825–1830. https://doi.org/10.1093/cid/civ678 PMID: 26627467

7. Butt AA, Ren Y, Pengpatom A, Arduino JM, Kumar R, Abu-Samra AB. Efficacy and safety of ledipasvir/sofosbuvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018 Jul; 48(1):35–43. https://doi.org/10.1111/apt.14799 PMID: 29797514

8. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012; 6(1):369–378. https://doi.org/10.1007/s12072-011-9284-9 PMID: 21698519

9. Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, et al. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int. 2018 Mar; 12(2):133–142. https://doi.org/10.1007/s12072-018-9859-9 PMID: 29600429

10. Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: Medicine, money, and advocacy. Clin Infect Dis. 2015; 61(12):1825–1830. https://doi.org/10.1093/cid/civ677 PMID: 26270682

11. But A, Ren Y, Pengpatom A, Arduino JM, Kumar R, Abu-Samra AB. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018 Jul; 48(1):35–43. https://doi.org/10.1111/apt.14799 PMID: 29797514

12. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study. Lancet. 2018; 393(10179):1453–1464. https://doi.org/10.1016/S0140-6736(18)32111-1 PMID: 30765123

13. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017; 152(1):142–156. https://doi.org/10.1053/j.gastro.2016.09.009 PMID: 27641509

14. Cheung MCM, Walker AJ, Hudson BE, Verma S, McAulchan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65(4):741–747. https://doi.org/10.1016/j.jhep.2016.06.019 PMID: 27398925

15. Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021; 384(11):1036–1052. https://doi.org/10.1056/NEJMra2003539 PMID: 33790456

16. Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, et al. Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020; 97(1):193–201. https://doi.org/10.1016/j.kint.2019.04.030 PMID: 31337501

17. Driedger M, Galanakis C, Cooper C. Direct acting antiviral HCV treatment does not influence renal function. Medicine (Baltimore). 2020; 99(22):e20436. https://doi.org/10.1097/MD.00000000000020436 PMID: 32481445
18. Medeiros T, Rosário NF, Saraiva GN, Andrade TG, Silva AA, Almeida JR. Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian “real-life” study. J Clin Pharm Ther. 2018; 43(5):707–713. https://doi.org/10.1111/jcpt.12697 PMID: 29737025

19. Liu CH, Lin JW, Liu CJ, Su TH, Wu JH, Tseng TC, et al. Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2022 Feb 4:S1542-3565(22)00109-4. https://doi.org/10.1016/j.cgh.2022.01.050 PMID: 35131346

20. Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020 May; 72(5):839–846. https://doi.org/10.1016/j.jhep.2019.11.014 PMID: 31790766

21. Kidney disease: Improving global outcomes hepatitis C working group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. 2018; 8(3):91–165.

22. Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, et al. Ribavirin: Past, present and future. World J Hepatol. 2016; 8(2):123–130. https://doi.org/10.4254/wjh.v8.i2.123 PMID: 26807208

23. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbu- vir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016; 36 (6):807–816. https://doi.org/10.1111/liv.13102 PMID: 26923436

24. Hernán M, Robins J. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016; 183(8):758–764. https://www.ncbi.nlm.nih.gov/pubmed/26994063. https://doi.org/10.1093/aje/kwv254 PMID: 26994063

25. Calner P, Sperring H, Ruiz-Mercado G, Miller N, Andry C, Battisti L, et al. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One. 2019; 14 (7):e0218388. https://doi.org/10.1371/journal.pone.0218388 PMID: 31291275

26. Sperring H, Ruiz-Mercado G, Schechter-Perkins E. Impact of the 2020 COVID-19 pandemic on ambulatory hepatitis C testing. J Prim Care Community Health. 2020; 11:2150132720969554. https://doi.org/10.1177/2150132720969554 PMID: 33252792

27. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, et al. A new equation to estimate g lomerular filtration rate. Ann Intern Med. 2009; 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 PMID: 19414839

28. Florkowsk i C, Chew-Harris J. Methods of estimating GFR—different equations including CKD-EPI. Clin Biochem Rev. 2011; 32(2):75–79. PMID: 21611080

29. Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, et al. Graphical depiction of lon- gitudinal study designs in health care databases. Ann Intern Med. 2019; 170(6):398–406. https://doi.org/10.7326/M18-3079 PMID: 30856654

30. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. Math comput model. 1986; 7(9–12):1393–1512. https://doi.org/10.1016/0270-0255(86)90088-6

31. Robins J, Hernán M. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, eds. Longitudinal data analysis. Boca Raton, Florida: Chapman & Hall; 2009:553–597.

32. Hernán M, Hernández-Díaz S, Robins J. A structural approach to selection bias. Epidemiology. 2004; 15(5):615–625. https://doi.org/10.1097/01.ede.0000135174.63482.43 PMID: 15308692

33. Young J, Cain L, Robins J, O’Reilly E, Hernán M. Comparative effectiveness of dynamic treat ment regimes: An application of the parametric g-formula. Stat Biosci. 2011; 3(1):119–143. https://doi.org/10.1007/s12561-011-9040-7 PMID: 24039638

34. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall A, et al. Comparative effectiveness of imme diate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: Observational cohort study. Lancet HIV. 2015; 2(8):e335–e343. https://doi.org/10.1016/S2352-3018(15)00108-3 PMID: 26423376

35. Taubman S, Robins J, Mittleman M, Hernán M. Intervening on risk factors for coronary heart disease: An application of the parametric g-formula. Int J Epidemiol. 2009; 38(6):1599–1611. https://doi.org/10.1093/ije/dyp192 PMID: 19389875

36. Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt AZ, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018; 55:31–39. https://doi.org/10.1016/j.drugpo.2018.02.001 PMID: 29482150

37. Logan R, Young J, Taubman S, Lodi S, Picciotto S, Danaei G, et al. GFORMULA 3.0—the parametric g-formula in SAS. https://www.hsph.harvard.edu/causal/software/. Updated 2019.
38. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. *Clin J Am Soc Nephrol*. 2012; 7 (3):401–408. https://doi.org/10.2215/CJN.07650711 PMID: 22282481

39. Lo Re V, Kallan M, Tate J, Localio A, Lim J, Goetz M, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. *Ann Intern Med*. 2014; 160(6):369–379. https://doi.org/10.7326/M13-1829 PMID: 24723077

40. Ward J, Mermin J. Simple, effective, but out of reach? public health implications of HCV drugs. *N Engl J Med*. 2015; 373(27):2678–2680. https://doi.org/10.1056/NEJMe1513245 PMID: 26575359

41. Zullig LL, Bhatia HL, Gellad ZF, Eatherly M, Henderson R, Bosworth HB. Adoption of direct-acting antiviral medications for hepatitis C: A retrospective observational study. *BMC Health Serv Res*. 2019; 19 (1):521. https://doi.org/10.1186/s12913-019-4349-x PMID: 31345218

42. Epstein R, Moloney C, Garfinkel J, Saia K, Wachman E, Lodi S, et al. Enhancing linkage to hepatitis C virus treatment following pregnancy in women identified during perinatal care. *Hepatol Commun*. 2021; 5(9):1543–1554. https://doi.org/10.1002/hep4.1748 PMID: 34510828